-
Veraxa Biotech receives regulatory guidance on BiTAC-TCE cancer therapy
-
VERAXA Biotech partners with Ardigen on AI drug discovery for cancer
-
VERAXA Biotech targets first BiTAC candidate IND-ready by 2028
-
Veraxa Biotech starts cell line development with ATUM for cancer therapy
-
VERAXA Biotech expands lab space at Heidelberg R&D site
-
VERAXA Biotech reports in vitro data for its BiTAC-ADC platform
-
VERAXA Biotech completes merger, begins NASDAQ trading

